June 14, 2006 — Two new drugs overcome the resistance that can develop to the first-line-therapy imatinib ( Gleevec, Novartis) in chronic myeloid leukemia (CML), and results from phase 1 clinical ...

NEW YORK, June 5 (Reuters) - Bristol-Myers Squibb's cancer drug Sprycel may be superior to the already highly effective standard medicine Gleevec in treating newly diagnosed patients with chronic ...

STOCKHOLM--(BUSINESS WIRE)--Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY), a Swedish pharmaceutical company which uses its innovative Hynap technology to develop 505(b)(2) improved versions of ...

The FDA's complete response letter for Dasynoc was due to manufacturing issues, delaying its approval for chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) treatment. Dasynoc, a ...

STOCKHOLM--(BUSINESS WIRE)-- Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY), a Swedish pharmaceutical company which uses its innovative Hynap technology to develop 505(b)(2) improved versions of ...

NEW YORK, June 5 (Reuters) - Bristol-Myers Squibb's cancer drug Sprycel was superior to the highly effective Gleevec in treating newly diagnosed patients with chronic myeloid leukemia, researchers ...

The leading Chronic Myeloid Leukemia Companies such as Kartos Therapeutics, AOP Orphan Pharmaceuticals, Biokine Therapeutics, ...

PHYRAGO™ Represents the First and Only Improved Version of SPRYCEL ® That Can Be Safely Co-administered With Gastric Acid-Reducing Agents TAIPEI, TAIWAN / ACCESSWIRE / January 15, 2025 / ...

A very unusual case of 2 chronic leukemias, chronic lymphocytic leukemia (CLL) and secondary chronic myeloid leukemia (CML) existing simultaneously in an older patient was treated with a pair of ...